|
1
|
Nandakumar B, Kumar SK, Dispenzieri A,
Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder
A, et al: Clinical characteristics and outcomes of patients with
primary plasma cell leukemia in the era of novel agent therapy.
Mayo Clin Proc. 96:677–687. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gonsalves WI, Rajkumar SV, Go RS,
Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P,
Dingli D, et al: Trends in survival of patients with primary plasma
cell leukemia: A population-based analysis. Blood. 124:907–912.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pagano L, Valentini CG, De Stefano V,
Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C,
Pogliani EM, et al: Primary plasma cell leukemia: A retrospective
multicenter study of 73 patients. Ann Oncol. 22:1628–1635.
2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mahindra A, Kalaycio ME, Vela-Ojeda J,
Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A,
Gajewski JL, et al: Hematopoietic cell transplantation for primary
plasma cell leukemia: Results from the Center for International
Blood and Marrow Transplant Research. Leukemia. 26:1091–1097.
2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Royer B, Minvielle S, Diouf M, Roussel M,
Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, et al:
Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction
followed by stem cell transplantation for primary plasma cell
leukemia: A prospective phase II study of the intergroupe
francophone du myelome. J Clin Oncol. 34:2125–2132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gowda L, Shah M, Badar I, Bashir Q, Shah
N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, et al:
Primary plasma cell leukemia: Autologous stem cell transplant in an
era of novel induction drugs. Bone Marrow Transplantation.
54:1089–1093. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jurczyszyn A, Radocha J, Davila J, Fiala
MA, Gozzetti A, Grzasko N, Robak P, Hus I, Waszczuk-Gajda A,
Guzicka-Kazimierczak R, et al: Prognostic indicators in primary
plasma cell leukaemia: A multicentre retrospective study of 117
patients. Br J Haematol. 180:831–839. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ganzel C, Rouvio O, Avivi I, Magen H,
Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, et
al: Primary plasma cell leukemia in the era of novel agents for
myeloma-a multicenter retrospective analysis of outcome. Leuk Res.
68:9–14. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mina R, Joseph NS, Kaufman JL, Gupta VA,
Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka
AK, et al: Survival outcomes of patients with primary plasma cell
leukemia (pPCL) treated with novel agents. Cancer. 125:416–423.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lemieux C, Johnston LJ, Lowsky R, Muffly
LS, Craig JK, Shiraz P, Rezvani A, Frank MJ, Weng WK, Meyer E, et
al: Outcomes with autologous or allogeneic stem cell
transplantation in patients with plasma cell leukemia in the era of
novel agents. Biol Blood Marrow Transplant. 26:e328–e332.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dhakal B, Patel S, Girnius S, Bachegowda
L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, et
al: Hematopoietic cell transplantation utilization and outcomes for
primary plasma cell leukemia in the current era. Leukemia.
34:3338–3347. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Katodritou E, Terpos E, Delimpasi S,
Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A,
Giannakoulas N, Vadikolia C, et al: Real-world data on prognosis
and outcome of primary plasma cell leukemia in the era of novel
agents: A multicenter national study by the Greek Myeloma Study
Group. Blood Cancer J. 8(31)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bento L, Boumendil A, Finel H, Khvedelidze
I, Blaise D, Fegueux N, Castagna L, Forcade E, Chevallier P,
Mordini N, et al: Tandem autologous-reduced intensity allogeneic
stem cell transplantation in high-risk relapsed Hodgkin lymphoma: A
retrospective study of the Lymphoma Working Party-EBMT. Bone Marrow
Transplant. 56:655–663. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
LeBlanc R, Ahmad I, Terra R, Boudreault
JS, Ogez D, Lamore K, Delisle JS, Bambace N, Bernard L, Cohen S, et
al: Outcomes in newly diagnosed young or high-risk myeloma patients
receiving tandem autologous/allogeneic transplant followed by
bortezomib maintenance: A phase II study. Bone Marrow Transplant.
57:252–260. 2022.PubMed/NCBI View Article : Google Scholar
|
